Literature DB >> 26163449

Activation of angiotensin II type 2 receptor suppresses TNF-α-induced ICAM-1 via NF-кB: possible role of ACE2.

Liping Zhu1, Oscar A Carretero2, Jiang Xu2, Pamela Harding2, Nithya Ramadurai2, Xiaosong Gu2, Edward Peterson3, Xiao-Ping Yang2.   

Abstract

ANG II type 2 receptor (AT2) and ANG I-converting enzyme 2 (ACE2) are important components of the renin-ANG system. Activation of AT2 and ACE2 reportedly counteracts proinflammatory effects of ANG II. However, the possible interaction between AT2 and ACE2 has never been established. We hypothesized that activation of AT2 increases ACE2 activity, thereby preventing TNF-α-stimulated ICAM-1 expression via inhibition of NF-κB signaling. Human coronary artery endothelial cells were pretreated with AT2 antagonist PD123319 (PD) or ACE2 inhibitor DX600 and then stimulated with TNF-α in the presence or absence of AT2 agonist CGP42112 (CGP). We found that AT2 agonist CGP increased both ACE2 protein expression and activity. This effect was blunted by AT2 antagonist PD. ICAM-1 expression was very low in untreated cells but greatly increased by TNF-α. Activation of AT2 with agonist CGP or with ANG II under concomitant AT1 antagonist reduced TNF-α-induced ICAM-1 expression, which was reversed by AT2 antagonist PD or ACE2 inhibitor DX600 or knockdown of ACE2 with small interfering RNA. AT2 activation also suppressed TNF-α-stimulated phosphorylation of inhibitory κB (p-IκB) and NF-κB activity. Inhibition of ACE2 reversed the inhibitory effect of AT2 on TNF-α-stimulated p-IκB and NF-κB activity. Our findings suggest that stimulation of AT2 reduces TNF-α-stimulated ICAM-1 expression, which is partly through ACE2-mediated inhibition of NF-κB signaling.
Copyright © 2015 the American Physiological Society.

Entities:  

Keywords:  ANG I-converting enzyme 2; ANG II type 2 receptor; ICAM-1; TNF-α

Mesh:

Substances:

Year:  2015        PMID: 26163449      PMCID: PMC4591403          DOI: 10.1152/ajpheart.00814.2014

Source DB:  PubMed          Journal:  Am J Physiol Heart Circ Physiol        ISSN: 0363-6135            Impact factor:   4.733


  46 in total

1.  Stimulation of different subtypes of angiotensin II receptors, AT1 and AT2 receptors, regulates STAT activation by negative crosstalk.

Authors:  M Horiuchi; W Hayashida; M Akishita; K Tamura; L Daviet; J Y Lehtonen; V J Dzau
Journal:  Circ Res       Date:  1999-04-30       Impact factor: 17.367

2.  Stimulation of AT2 receptor exerts beneficial effects in stroke-prone rats: focus on renal damage.

Authors:  Paolo Gelosa; Alice Pignieri; Lars Fändriks; Marc de Gasparo; Anders Hallberg; Cristina Banfi; Laura Castiglioni; Lucia Turolo; Uliano Guerrini; Elena Tremoli; Luigi Sironi
Journal:  J Hypertens       Date:  2009-12       Impact factor: 4.844

3.  Role of the angiotensin II AT2 receptor in inflammation and oxidative stress: opposing effects in lean and obese Zucker rats.

Authors:  Rifat Sabuhi; Quaisar Ali; Mohammad Asghar; Najah Riesh Hadi Al-Zamily; Tahir Hussain
Journal:  Am J Physiol Renal Physiol       Date:  2011-01-05

4.  Human vascular endothelial cells produce tumor necrosis factor-alpha in response to proinflammatory cytokine stimulation.

Authors:  V Ranta; A Orpana; O Carpén; U Turpeinen; O Ylikorkala; L Viinikka
Journal:  Crit Care Med       Date:  1999-10       Impact factor: 7.598

Review 5.  ACE2/ANG-(1-7)/Mas pathway in the brain: the axis of good.

Authors:  Ping Xu; Srinivas Sriramula; Eric Lazartigues
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2010-12-22       Impact factor: 3.619

6.  Angiotensin II type 2 receptor-stimulated activation of plasma prekallikrein and bradykinin release: role of SHP-1.

Authors:  Liping Zhu; Oscar A Carretero; Jiang Xu; Luchen Wang; Pamela Harding; Nour-Eddine Rhaleb; James J Yang; Colin Sumners; Xiao-Ping Yang
Journal:  Am J Physiol Heart Circ Physiol       Date:  2012-04-20       Impact factor: 4.733

7.  Cloning and characterization of a secreted form of angiotensin-converting enzyme 2.

Authors:  Matthew J Huentelman; Jasenka Zubcevic; Michael J Katovich; Mohan K Raizada
Journal:  Regul Pept       Date:  2004-10-15

Review 8.  ACE2, angiotensin-(1-7) and Mas receptor axis in inflammation and fibrosis.

Authors:  A C Simões e Silva; K D Silveira; A J Ferreira; M M Teixeira
Journal:  Br J Pharmacol       Date:  2013-06       Impact factor: 8.739

Review 9.  Smad7 as a therapeutic agent for chronic kidney diseases.

Authors:  Hui Yao Lan
Journal:  Front Biosci       Date:  2008-05-01

Review 10.  The inflammatory aspect of the microcirculation in hypertension: oxidative stress, leukocytes/endothelial interaction, apoptosis.

Authors:  Makoto Suematsu; Hidekazu Suzuki; Frank A Delano; Geert W Schmid-Schönbein
Journal:  Microcirculation       Date:  2002       Impact factor: 2.628

View more
  15 in total

Review 1.  Perspectives: potential therapeutic approach with inhalation of ACE2-derived peptides for SARS-CoV-2 infection.

Authors:  Rossella Talotta; Erle S Roberston
Journal:  Am J Clin Exp Immunol       Date:  2020-12-15

2.  Angiotensin receptor blockade mediated amelioration of mucopolysaccharidosis type I cardiac and craniofacial pathology.

Authors:  Mark J Osborn; Beau R Webber; Ronald T McElmurry; Kyle D Rudser; Anthony P DeFeo; Michael Muradian; Anna Petryk; Benedikt Hallgrimsson; Bruce R Blazar; Jakub Tolar; Elizabeth A Braunlin
Journal:  J Inherit Metab Dis       Date:  2016-10-14       Impact factor: 4.982

3.  Effects of sevoflurane on NF-кB and TNF-α expression in renal ischemia-reperfusion diabetic rats.

Authors:  Yu Zhang; Fang Hu; Jianghua Wen; Xiaohong Wei; Yingjuan Zeng; Ying Sun; Shunkui Luo; Liao Sun
Journal:  Inflamm Res       Date:  2017-07-06       Impact factor: 4.575

4.  Immunomodulatory and Mechanistic Considerations of Hibiscus sabdariffa (HS) in Dysfunctional Immune Responses: A Systematic Review.

Authors:  Francis U Umeoguaju; Benson C Ephraim-Emmanuel; Joy O Uba; Grace E Bekibele; Nwondah Chigozie; Orish Ebere Orisakwe
Journal:  Front Immunol       Date:  2021-05-10       Impact factor: 7.561

5.  Angiotensin-converting enzyme 2 inhibits high-mobility group box 1 and attenuates cardiac dysfunction post-myocardial ischemia.

Authors:  Yan Fei Qi; Juan Zhang; Lei Wang; Vinayak Shenoy; Eric Krause; S Paul Oh; Carl J Pepine; Michael J Katovich; Mohan K Raizada
Journal:  J Mol Med (Berl)       Date:  2016-01       Impact factor: 4.599

Review 6.  Vasculopathy and Coagulopathy Associated with SARS-CoV-2 Infection.

Authors:  Nazzarena Labò; Hidetaka Ohnuki; Giovanna Tosato
Journal:  Cells       Date:  2020-06-30       Impact factor: 6.600

7.  Angiotensin II type 2 receptor agonist Compound 21 attenuates pulmonary inflammation in a model of acute lung injury.

Authors:  Mario Menk; Jan Adriaan Graw; Clarissa von Haefen; Hendrik Steinkraus; Burkhard Lachmann; Claudia D Spies; David Schwaiberger
Journal:  J Inflamm Res       Date:  2018-05-01

8.  Physiological cyclic stretch up-regulates angiotensin-converting enzyme 2 expression to reduce proliferation and migration of vascular smooth muscle cells.

Authors:  Jiantao Song; Haiyan Qu; Bo Hu; Chenglong Bi; Mengmeng Li; Lin Wang; Xiaozhen Huang; Mei Zhang
Journal:  Biosci Rep       Date:  2020-06-26       Impact factor: 3.840

9.  An epidemiological study exploring a possible impact of treatment with ACE inhibitors or angiotensin receptor blockers on ACE2 plasma concentrations.

Authors:  Philipp S Wild; Stefanie Dimmeler; Thomas Eschenhagen
Journal:  J Mol Cell Cardiol       Date:  2020-04-05       Impact factor: 5.000

Review 10.  Small Resistance Artery Disease and ACE2 in Hypertension: A New Paradigm in the Context of COVID-19.

Authors:  María Galán; Francesc Jiménez-Altayó
Journal:  Front Cardiovasc Med       Date:  2020-10-30
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.